• AZTherapies Doses First Patient in ALZT-OP1a Study for ALS americanpharmaceuticalreview
    September 16, 2020
    AZTherapies announced the dosing of the first patient in its Phase 2a clinical trial examining the safety and efficacy of ALZT-OP1a in patients with mild- to moderate-stage Amyotrophic Lateral Sclerosis (ALS).
PharmaSources Customer Service